Bausch + Lomb Introduces Zenlens CHROMA HOA Lenses in U.S.

Bausch + Lomb Corporation ( (BLCO) ) just unveiled an update.

Bausch + Lomb has announced the U.S. launch of Zenlens CHROMA HOA scleral contact lenses, designed to correct advanced higher-order aberrations (HOA) and improve vision clarity by reducing symptoms like halos and glare. This new product fills a critical gap in scleral lens vision correction, offering eye care professionals a solution for patients with complex corneal irregularities. The company is collaborating with Advance Medical and OVITZ to integrate this technology into practices, enhancing its market position in the specialty lens sector.

The most recent analyst rating on (BLCO) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.

Spark’s Take on BLCO Stock

According to Spark, TipRanks’ AI Analyst, BLCO is a Neutral.

Bausch + Lomb’s overall score reflects solid revenue growth and a strong gross margin, but significant challenges in profitability and cash flow. Technical analysis shows bearish trends, while valuation metrics indicate poor earnings performance. The earnings call provided some optimism with growth in key segments, though risks remain from Pharmaceuticals and tariff pressures.

To see Spark’s full report on BLCO stock, click here.

More about Bausch + Lomb Corporation

Bausch + Lomb Corporation is a leading global eye health company dedicated to helping people see better to live better. The company focuses on providing innovative eye care solutions, including contact lenses and other vision correction products, to improve the quality of life for its customers.

Average Trading Volume: 861,624

Technical Sentiment Signal: Sell

Current Market Cap: $4.2B

See more data about BLCO stock on TipRanks’ Stock Analysis page.